X T L Biopharmaceuticals Ltd
TASE:XTLB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
X
|
X T L Biopharmaceuticals Ltd
TASE:XTLB
|
IL |
|
L1 Group Ltd
F:PIJ0
|
AU |
|
Amfil Technologies Inc
OTC:FUNN
|
CA |
|
D
|
DPC Dash Ltd
HKEX:1405
|
CN |
|
H
|
Hugo Boss AG
F:BOSS
|
DE |
|
C
|
Core Laboratories Inc
F:HJ1
|
US |
|
H
|
Honkarakenne Oyj
OMXH:HONBS
|
FI |
|
Novavax Inc
NASDAQ:NVAX
|
US |
|
C
|
CVC Capital Partners PLC
AEX:CVC
|
JE |
|
Vonovia SE
XETRA:VNA
|
DE |
|
Dave Inc
NASDAQ:DAVE
|
US |
|
O
|
Oak Street Health Inc
F:HE6
|
US |
|
F
|
Finnair Oyj
OMXH:FIA1S
|
FI |
|
Diligent Media Corporation Ltd
NSE:DNAMEDIA
|
IN |
|
Guangdong Fenghua Advanced Technology Holding Co Ltd
SZSE:000636
|
CN |
|
H & M Hennes & Mauritz AB
STO:HM B
|
SE |
|
BioArctic AB
STO:BIOA B
|
SE |
|
R
|
Royal Hotel Ltd
TSE:9713
|
JP |
|
B
|
BillionToOne Inc
NASDAQ:BLLN
|
US |
|
Roblon A/S
CSE:RBLN B
|
DK |
|
B
|
Black Pearl SA
WSE:BPC
|
PL |
|
Par Drugs and Chemicals Ltd
NSE:PAR
|
IN |
X T L Biopharmaceuticals Ltd
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS). hCDR1 is a peptide (short protein) that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS). hCDR1 is a peptide (short protein) that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
